雜志介紹

Molecular Cancer Research雜志介紹

《Molecular Cancer Research》是一本以English為主的未開放獲取國際優(yōu)秀期刊，中文名稱分子癌癥研究，本刊主要出版、報(bào)道醫(yī)學(xué)-CELL BIOLOGY領(lǐng)域的研究動(dòng)態(tài)以及在該領(lǐng)域取得的各方面的經(jīng)驗(yàn)和科研成果，介紹該領(lǐng)域有關(guān)本專業(yè)的最新進(jìn)展，探討行業(yè)發(fā)展的思路和方法，以促進(jìn)學(xué)術(shù)信息交流，提高行業(yè)發(fā)展。該刊已被國際權(quán)威數(shù)據(jù)庫SCIE收錄，為該領(lǐng)域相關(guān)學(xué)科的發(fā)展起到了良好的推動(dòng)作用，也得到了本專業(yè)人員的廣泛認(rèn)可。該刊最新影響因子為4.1，最新CiteScore 指數(shù)為9.9。

本刊近期中國學(xué)者發(fā)表的論文主要有：

• Hypertension Promotes the Proliferation and Migration of ccRCC Cells by Downregulation of TIMP3 in Tumor Endothelial Cells through the miR-21-5p/TGFBR2/P38/EGR1 Axis

  Author: Wang, Chenguang; Xu, Haibo; Liao, Xinhui; Wang, Weiming; Wu, Wanjun; Li, Wujiao; Niu, Liman; Li, Zhichao; Li, Aolin; Sun, Yangyang; Huang, Weiren; Song, Fei

• Sohlh2 Regulates the Stemness and Differentiation of Colon Cancer Stem Cells by Downregulating LncRNA-H19 Transcription

  Author: Zhang, Ruihong; Zhang, Xiaoli; Zhang, Wenfang; Cui, Weiwei; Xiao, Yunling; Liu, Lanlan; Zhi, Sujuan; Feng, Xiaoning; Liu, Xuyue; Shen, Ying; Chai, Jie; Hao, Jing

• XIAP and PHB1 Regulate Anoikis through Competitive Binding to TRAF6

  Author: Yang, Bo; Lou, Chao; Chen, Shengkai; Zhang, Zhiyuan; Xu, Qin

• Exosomal lincROR Promotes Docetaxel Resistance in Prostate Cancer through a beta-catenin/HIF1 alpha Positive Feedback Loop

  Author: Jiang, Xingkang; Xu, Yong; Liu, Ranlu; Guo, Shanqi

英文介紹

Molecular Cancer Research雜志英文介紹

Molecular Cancer Research publishes articles describing novel basic cancer research discoveries of broad interest to the field. Studies must be of demonstrated significance, and the journal prioritizes analyses performed at the molecular and cellular level that reveal novel mechanistic insight into pathways and processes linked to cancer risk, development, and/or progression. Areas of emphasis include all cancer-associated pathways (including cell-cycle regulation; cell death; chromatin regulation; DNA damage and repair; gene and RNA regulation; genomics; oncogenes and tumor suppressors; signal transduction; and tumor microenvironment), in addition to studies describing new molecular mechanisms and interactions that support cancer phenotypes. For full consideration, primary research submissions must provide significant novel insight into existing pathway functions or address new hypotheses associated with cancer-relevant biologic questions.